Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype that will respond to immune-based interventionSAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. NASDAQ:ONCY (“Oncolytics” or the “Company”), a clinical…